CLAIMS

1. Use of a compound of general formula (I):



wherein R_1 and R'_1 are independently hydrogen or C_1-C_6alkyl; R_2 is



optionally substituted with C_1-C_6alkyl,

or a pharmaceutically acceptable salt thereof for the manufacture of a therapeutic agent for the treatment of eosinophilic diseases,

wherein the eosinophilic disease is selected from the group consisting of bronchial asthma, allergic rhinitis, polypous rhinosinusopathies, atopic dermatitis, and eosinophilic esophagitis.

2. The use of claim 1, wherein R_1 and R'_1 are independently hydrogen or methyl, and R_2 is



.

3. The use of claim 1, wherein the compound of general formula (I) or the pharmaceutically acceptable salt is

selected from the group consisting of the following compounds:

Structure
